Uncategorized

BGM – Consumer product or medical device

Long ago Diabetic Investor took the position that blood glucose monitors had made the transition from a medical device market to a consumer product market. Today it’s commonplace to see television commercials for meters as BGM companies seek to establish brand name awareness. With competition intensifying it should come as no surprise that Abbott (NYSE:ABT) has taken the next step in consumer marketing, namely the use of coupons. Long a...

BD Exits BGM Market

This morning Becton Dickinson (NYSE:BDX) announced plans to exit the blood glucose monitoring (BGM) market. Diabetic Investor applauds this decision and sees BD’s core syringe and needle business as exceptionally strong. As the company stated during their conference call the exit from BGM market will not preclude them from pursuing other diabetes related products. The company does have a continuous glucose monitoring system under development and has expressed interest in...

The elusive quest for a cure

In today’s New England Journal of Medicine there’s an excellent article Diabetes Cure- Is the Glass Half Full? by Jonathan S Broomberg, M.D., Ph.D. and Derek LeRoith, M.D., Ph.D. The article discusses the potential and pitfalls of islet cell transplants. Back in 2000, a group at the University of Alberta in Edmonton, Canada, published a study which demonstrated that islet transplantation could be a cure for diabetes. After years...

The elusive quest for a cure

In today’s New England Journal of Medicine there’s an excellent article Diabetes Cure- Is the Glass Half Full? by Jonathan S Broomberg, M.D., Ph.D. and Derek LeRoith, M.D., Ph.D. The article discusses the potential and pitfalls of islet cell transplants. Back in 2000, a group at the University of Alberta in Edmonton, Canada, published a study which demonstrated that islet transplantation could be a cure for diabetes. After years...

A Call To Action

In Monday's issue of the Archives of Internal Medicine, the issue features a group of studies on patients who stopped taking their medications. One of the studies reviewed medical records of 11,532 diabetes patients. It found that those who didn't take their drugs--hypoglycemics, blood pressure drugs and statins--had higher rates of hospitalization and death. The link was not as pronounced as in the heart attack research, but was still significant....

HDI IPO

This morning blood glucose monitoring company Home Diagnostics, Inc. made its debut on the NASDAQ trading under the symbol HDIX. The initial public offering was priced at $12 and the stock is currently trading slightly higher. The $12 per share initial price was lower than analysts had estimated and could be viewed as a sign of just how difficult the BGM market has become. Diabetic Investor has received several inquires...

Navigator Update

Investor has learned from well placed sources inside Abbott (NYSE:ABT) that the Navigator continuous monitoring device currently awaiting FDA approval has been delayed until at least November and more likely December. This is just the latest in series of setbacks for the Navigator and puts them further behind Medtronic (NYSE:MDT) and Dexcom (NASDAQ:DXCM) both of whom have FDA approved CGMS systems available. According to our source the FDA is seeking...

LifeScan – The Future and few surprises

This afternoon at Johnson and Johnson’s (NYSE:JNJ) Medical Devices and Diagnostics Business Review, Eric Milledge Group Chairman responsible for the LifeScan unit provided a glimpse of the future. Here are the highlights: 1. 1. Although Mr. Milledge mentioned that LifeScan new focus is to become a disease management company it appears JNJ’s definition of disease management is far different than conventional disease management and looks similar to...

BD Reports

This morning Becton Dickinson (NYSE:BDX) reported their fiscal fourth quarter and full years results. Although the company has made the decision to exit the blood glucose monitoring market, BD is hardly shying away from the diabetes sector. Already the leader in the needle and syringe segment, the company continues to explore opportunities in the insulin delivery and continuous glucose monitoring market. Trends in diabetes management are definitely in BD’s...

An Important Day

Today in our nations capital a meeting is taking place that has far reaching implications for the continuous glucose monitoring market. The Medicare Coverage Advisory Committee is meeting to consider the potential impact of continuous monitoring. Although no binding decision is expected today this is the first of many steps towards CGM receiving reimbursement. Many, including Diabetic Investor, believe without reimbursement the market for CGM will be limited to a...